Metabolic implications of obesity: Before and after gastric bypass

Gastroenterology Clinics of North America

Volumn 34, Issue 1, 2005, Pages 9-24

  Richardson, Donald W ^a   Vinik, Aaron I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; AMFEPRAMONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CAFFEINE; CATECHOLAMINE DERIVATIVE; EPHEDRINE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAZINDOL; METFORMIN; NORADRENALIN UPTAKE INHIBITOR; PHENTERMINE; SEROTONIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIET; ENERGY EXPENDITURE; EXERCISE; FATTY ACID METABOLISM; FEEDING BEHAVIOR; FOLLOW UP; GLUCOSE METABOLISM; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HEART ARRHYTHMIA; HORMONE METABOLISM; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; POLITICS; PREVALENCE; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SLEEP APNEA SYNDROME; SLEEP DISORDER; STOMACH BYPASS; SURGICAL TECHNIQUE; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; X RAY ANALYSIS;

EID: 16844374246     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.12.009     Document Type: Review

References (94)

1. K.M. Flegal, M.D. Carroll, and C.L. Ogden Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 14 2002 1723 1727
2. S. Haffner, and H. Taegtmeyer Epidemic obesity and the metabolic syndrome Circulation 108 2003 1541 1545
3. T.A. Jacobson, C.C. Case, and S. Roberts Characteristics of US adults with the metabolic syndrome and therapeutic implications Diabetes Obes Metab 6 5 2004 353 362
4. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 3 2002 356 359
5. P. James, N. Rigby, and R. Leach The obesity epidemic, metabolic syndrome and future prevention strategies European Journal of CV Prevention 11 2004 3 8
6. A.H. Mokdad, E.S. Ford, and B.A. Bowman Diabetes trends in the US: 1990-1998 Diabetes Care 23 2000 1278 1283
7. A.H. Mokdad, E.S. Ford, and B.A. Bowman Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 JAMA 289 1 2003 76 79
8. A.H. Mokdad, B.A. Bowman, and E.S. Ford The continuing epidemics of obesity and diabetes in the United States JAMA 286 10 2001 1195 1200
9. E.S. Ford, A.H. Mokdad, and W.H. Giles Trends in waist circumference among US adults Obes Res 11 10 2003 1223 1231
10. E.S. Ford, D.F. Williamson, and S. Liu Weight change and diabetes incidence: findings from a national cohort of US adults Am J Epidemiol 146 1997 214 222
11. Centers for Disease Control and Prevention Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000 MMWR Morb Mortal Wkly Rep 52 35 2003 833 837
12. W.C. Willett, W.H. Dietz, and G.A. Colditz Guidelines for healthy weight N Engl J Med 341 6 1999 427 434
13. A.E. Field, E.H. Coakley, and A. Must Impact of overweight on the risk of developing common chronic diseases during a 10-year period Arch Intern Med 161 13 2001 1581 1586
14. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1602
15. J. Chen, P. Muntner, and L.H. Hamm The metabolic syndrome and chronic kidney disease in US adults Ann Intern Med 140 2004 167 174
16. A.I. Vinik, T. Erbas, and T.S. Park Dermal neurovascular dysfunction in type 2 diabetes Diabetes Care 24 8 2001 1468 1475
17. National Institutes of Health Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary JAMA 285 19 2001 2486 2497
18. B. Isomaa, P. Almgren, and K. Lahti Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
19. C. Glueck, R. Papanna, and P. Wang Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome Metabolism 52 7 2003 908 915
20. J.B. Dixon, P.S. Bhathal, and P.E. O'Brien Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese Gastroenterology 121 1 2001 91 100
21. J. Medina, L. Garcia-Buey, and L. Fernandez-Salazar Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis Diabetes Care 27 2004 2057 2066
22. I.A. Harsch, S.P. Schahin, and K. Bruckner The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnea syndrome and type 2 diabetes Respiration 71 3 2004 252 259
23. Y. Zhang, R. Proenca, and M. Maffei Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425 432
24. D.S. Weigle, T.R. Bukowski, and D.C. Foster Recombinant ob protein reduces feeding and body weight in the ob/ob mouse J Clin Invest 96 4 1995 2065 2070
25. J. Licinio, S. Caglayan, and M. Ozata Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults Proc Natl Acad Sci U S A 101 13 2004 4531 4536
26. D.E. Cummings, and M.W. Schwartz Genetics and pathophysiology of human obesity Annu Rev Med 54 2003 453 471
27. G.A. Bray Obesity is a chronic, relapsing neurochemical disease Int J Obes Relat Metab Disord 28 1 2004 34 38
28. L.S. Gross, L. Li, and E.S. Ford Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment Am J Clin Nutr 79 5 2004 774 779
29. G.A. Bray, S.J. Nielsen, and B.M. Popkin Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity Am J Clin Nutr 79 4 2004 537 543
30. S.J. Marshall, S.J. Biddle, and T. Gorely Relationships between media use, body fatness and physical activity in children and youth: a meta-analysis Int J Obes Relat Metab Disord 28 10 2004 1238 1246
31. C. Bjørbæk, and B.B. Kahn Leptin Signaling in the Central Nervous System and the Periphery Recent Prog Horm Res 59 2004 305 331
32. E.E. Kershaw, and J.S. Flier Adipose Tissue as an Endocrine Organ J Clin Endocrinol Metab 89 2004 2548-55
33. J.J. Díez, and P. Iglesias The role of the novel adipocyte-derived hormone adiponectin in human disease Eur J Endocrinol 148 3 2003 293 300
34. G.H. Goossens, E.E. Blaak, and M.A. van Baak Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders Obes Rev 4 1 2003 43 55
35. C. Belanger, V. Luu-The, and P. Dupont Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity Horm Metab Res 34 2002 737 745
36. A. Meseguer, C. Puche, and A. Cabero Sex steroid biosynthesis in white adipose tissue Horm Metab Res 34 2002 731 736
37. D.E. Laaksonen, L. Niskanen, and K. Punnonen Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men Diabetes Care 27 2004 1036 1041
38. E.C. Tsai, A.M. Matsumoto, and W.Y. Fujimoto Association of bioavailable, free, and total testosterone with insulin resistance. Influence of sex hormone-binding globulin and body fat Diabetes Care 27 2004 861 868
39. P. Bjorntorp Endocrine abnormalities of obesity Metabolism 44 1995 21 23
40. T.M. Stulnig, and W. Waldhausl 11β-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes Diabetologia 47 2004 1 11
41. J.R. Seckl, and B.R. Walker Minireview: 11β-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action Endocrinology 142 2001 1371 1376
42. A.D. Karelis, D.H. St-Pierre, and F. Conus Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 89 2004 2569 2575
43. E. Mor, A. Zograbyan, and P. Saadat The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis Am J Obstet Gynecol 190 2004 1654 1660
44. M.C. Carr, and J.D. Brunzell Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk J Clin Endocrinol Metab 89 2004 2601 2607
45. A. Dresner, D. Laurent, and M. Marcucci Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity J Clin Invest 103 1999 253 259
46. P.J. Randle, P.B. Garland, and C.N. Hales The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet I 1963 785 789
47. Prospective Diabetes Study UK Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
48. Officers ALLHAT and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
49. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 2002 393 403
50. R. Padwal, S.K. Li, and D.C.W. Lau Long-term pharmacotherapy for obesity and overweight (Cochrane Review) The Cochrane Library 2004 3 CD004094
51. K.M. McTigue, R. Harris, and B. Hemphill Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force Ann Intern Med 139 11 2003 933 949
52. P.G. Shekelle, M.L. Hardy, and S.C. Morton Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis JAMA 289 12 2003 1537 1545
53. C.S. Coffey, D. Steiner, and B.A. Baker A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment Int J Obes Relat Metab Disord 28 11 2004 1411 1419
54. B.H. Sindler Herbal therapy for management of obesity: observations from a clinical endocrinology practice Endocr Pract 7 6 2001 443 447
55. S. Bent, T.N. Tiedt, and M.C. Odden The relative safety of ephedra compared with other herbal products Ann Intern Med 138 6 2003 468 471
56. S.L. Norris, X. Zhang, and A. Avenell Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis Arch Intern Med 164 13 2004 1395 1404
57. B. Guy-Grand, P. Drouin, and E. Eschwege Effects of orlistat on obesity-related diseases - a six-month randomized trial Diabetes Obes Metab 6 5 2004 375 383
58. J.L. Chiasson, R.G. Josse, and R. Gomis STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 4 2003 486 494
59. L. Howard, M. Malone, and A. Michalek Gastric bypass and vertical banded gastroplasty - a prospective randomized comparison and 5-year follow-up Obes Surg 5 1 1995 55 60
60. J.F. Capella, and R.F. Capella An assessment of vertical banded gastroplasty-Roux-en-Y gastric bypass for the treatment of morbid obesity Am J Surg 183 2 2002 117 123
61. E.W. Gregg, R.B. Gerzoff, and T.J. Thompson Intentional weight loss and death in overweight and obese US, adults 35 years of age and older Ann Intern Med 138 5 2003 383 389
62. C.D. Sjostrom, M. Peltonen, and H. Wedel Differentiated long-term effects of intentional weight loss on diabetes and hypertension Hypertension 36 1 2000 20 25
63. C.D. Sjostrom, L. Lissner, and L. Sjostrom Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects Obes Res 5 1997 519 530
64. G.A. Bray Medical consequences of obesity J Clin Endocrinol Metab 89 2004 2583 2589
65. J. Tuomilehto, J. Lindstrom, and J.G. Eriksson Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
66. C.E. Koro, S.J. Bowlin, and N. Bourgeois Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes Diabetes Care 27 2004 17 20
67. B.M. Balsiger, F.P. Kennedy, and H.S. Abu-Lebdeh Prospective evaluation of Roux-en-Y gastric bypass as primary operation for medically complicated obesity Mayo Clin Proc 75 7 2000 673 680
68. L. Howard, M. Malone, and A. Michalek Gastric bypass and vertical banded gastroplasty: a prospective randomized comparison and 5-year follow-up Obes Surg 5 1995 55 56
69. H.J. Sugerman, E.J. DeMaria, and J.M. Kellum Effects of bariatric surgery in older patients Ann Surg 240 2 2004 243 247
70. H.J. Sugerman, L.G. Wolfe, and D.A. Sica Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss Ann Surg 237 6 2003 751 758
71. V. Giusti, M. Suter, and E. Heraief Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months follow-up Obes Surg 14 2 2004 239 245
72. P.R. Schauer, B. Burguera, and S. Ikramuddin Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus Ann Surg 238 2003 467 484
73. S.E. Greenway, F.L. Greenway 3rd, and S. Klein Effects of obesity surgery on non-insulin-dependent diabetes mellitus Arch Surg 137 2002 1109 1117
74. W.J. Pories Diabetes: the evolution of a new paradigm Ann Surg 239 1 2004 12 13
75. H.J. Sugerman, L.G. Wolfe, and D.A. Sica Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss Ann Surg 237 2003 751 756
76. C.D. Sjostrom, M. Peltonen, and H. Wedel Differentiated long-term effects of intentional weight loss on diabetes and hypertension Hypertension 36 2000 20 25
77. M.R. Letiexhe, C. Desaive, and P.J. Lefebvre Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients Int J Obes Relat Metab Disord 28 2004 821 823
78. D.E. Kelley Influence of weight loss and physical activity interventions upon muscle lipid content in relation to insulin resistance Curr Diab Rep 4 2004 165 168
79. C. Pender, I.D. Goldfine, and C.J. Tanner Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia Int J Obes Relat Metab Disord 28 2004 363 369
80. D.R. Cottam, S.G. Mattar, and E. Barinas-Mitchell The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss Obes Surg 14 2004 589 600
81. F.M. van Dielen, W.A. Buurman, and M. Hadfoune Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery J Clin Endocrinol Metab 89 2004 4062 4068
82. J. Crespo, P. Fernandez-Gil, and M. Hernandez-Guerra Are there predictive factors of severe liver fibrosis in morbidly obese patients with nonalcoholic steatohepatitis? Obes Surg 11 2001 254 257
83. L. Spaulding, T. Trainer, and D. Janiec Prevalence of nonalcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass Obes Surg 13 2003 347 349
84. S. Shalhub, A. Parsee, and S.F. Gallagher The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients Obes Surg 14 2004 54 59
85. M. Vyberg, V. Ravn, and B. Andersen Pattern of progression in liver injury following jejunoileal bypass for morbid obesity Liver 7 5 1987 271 276
86. M.M. Huber-Buchholz, D.G.P. Carey, and R.J. Norman Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone J Clin Endocrinol Metab 84 1999 1470 1474
87. L.J. Moran, M. Noakes, and P.M. Clifton Short-term energy restriction (using meal replacements) improves reproductive parameters in polycystic ovary syndrome Asia Pac J Clin Nutr 13 Suppl 2004 S88
88. K.M. Hoeger, L. Kochman, and N. Wixom A randomized 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study Fertil Steril 82 2004 421 429
89. E. Sheiner, A. Levy, and D. Silverberg Pregnancy after bariatric surgery is not associated with adverse perinatal outcome Am J Obstet Gynecol 190 2004 1335 1340
90. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
91. R.P. Robertson, C. Davis, and J. Larsen Pancreas and islet transplantation for patients with diabetes mellitus Diabetes Care 23 2000 112 116
92. N.V. Christou, J.S. Sampalis, and M. Liberman Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients Ann Surg 240 2004 416 423
93. Kaiser Commission on Medicaid and the Uninsured. The President's FY 2005 budget proposal: overview and briefing charts. Kaiser Family Foundation; Washington, DC. June 2004.
94. C. Rowland FDA chief looks to speed diabetes, obesity drugs Globe June 4, 2003 A1